These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31622099)

  • 1. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
    Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
    J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
    Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
    J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
    Degorce SL; Anjum R; Dillman KS; Drew L; Groombridge SD; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Scott JS; Stokes S; Xue Y
    Bioorg Med Chem; 2018 Feb; 26(4):913-924. PubMed ID: 29398441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
    Degorce SL; Aagaard A; Anjum R; Cumming IA; Diène CR; Fallan C; Johnson T; Leuchowius KJ; Orton AL; Pearson S; Robb GR; Rosen A; Scarfe GB; Scott JS; Smith JM; Steward OR; Terstiege I; Tucker MJ; Turner P; Wilkinson SD; Wrigley GL; Xue Y
    Bioorg Med Chem; 2020 Dec; 28(23):115815. PubMed ID: 33091850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
    Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
    Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.
    Weiss MM; Zheng X; Ji N; Browne CM; Campbell V; Chen D; Enerson B; Fei X; Huang X; Klaus CR; Li H; Mayo M; McDonald AA; Paul A; Rong H; Sharma K; Shi Y; Slavin A; Walther DM; Yuan K; Zhang Y; Zhu X; Kelleher J; Walker D; Mainolfi N
    J Med Chem; 2024 Jul; 67(13):10548-10566. PubMed ID: 38920289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
    Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
    Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
    Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
    Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
    J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
    Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.
    Fu L; Zhang J; Shen B; Kong L; Liu Y; Tu W; Wang W; Cai X; Wang X; Cheng N; Xia M; Zhou T; Liu Q; Xu Y; Yang J; Gavine P; Philippar U; Attar R; Edwards JP; Venable JD; Dai X
    J Med Chem; 2021 Aug; 64(15):10878-10889. PubMed ID: 34279092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.